Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
August 29
Marc ZERBOLA CHALLANDE
On August 29, Cannibble Foodtech (PLCN.CN) announced important news. The company declared a Letter Of Intent (LOI) to acquire Eshbal Functional Foods, an Israeli food tech manufacturer. Cannibble, which aims to position itself as a leader in the US health and wellness “better-for-you” market, reaches an important milestone. If the stock remained discrete since its IPO, it should bring more interest from investors.
Cannibble Foodtech is an Israeli food tech company developing and manufacturing powder mix food products enhanced with hemp seeds, hemp protein, and other legal ingredients. Cannibble Foodtech already has commercial sales in the US, including Amazon and Sam’s Club warehouses in Puerto Rico stores. The company intends to dive deeper into Puerto Rico by retaining Crossmark to conduct in-club promotional event planning and demo services to promote Pelicann™ product sales. Crossmark is a leading US sales and marketing services agency specializing in growing retail brands throughout nearly every category of the consumer goods industry. In August, the company continued its international expansion, with its first commercial order coming from Australia. The client, who sells mainly online and imports health, wellness, and keto food products to Australia, placed the demand for the entire range of the Pelicann™ Hempshake and Hemp mix products which fits the distributor’s line of products such as sugar-free, dairy-free, plant-based and non-GMO products.
The company has 100 different formulations already developed and ready to introduce to the market, which will satisfy many customers.
Cannibble’s line of products is marketed under its brand name “The Pelicann” and offers five categories of products:
Eshbal Functional Foods develops and manufactures advanced food products and dietary supplements, using diverse manufacturing and packaging methods customized to meet all customer needs with precision and accuracy. The company was established as the Galam Packaging Company in 1940 in Kibbutz Ma’anit, Israel. It was acquired in 2014 by a private group of investors from the food and food technology sector. Eshbal already exports its products to the United States, Spain, Russia, Ukraine, Denmark, and other countries. It is good also to mention the company is under strict regulatory standards and requirements, including ISO 9001:2008, ISO/TS 22002-1:2008, Hazard Analysis Critical Control Point* (HACCP) and Good Manufacturing Practices** (GMPs). Tomer Bar-Meir, the CEO, leads Eshbal Functional Foods.
Cannibble Foodtech, through its news release, will operate this way: the proposed acquisition will be an all-shares transaction, with the vendors receiving in the aggregate ordinary shares of Cannibble equal to 50% of the issued and outstanding Cannibble shares at the closing of the proposed acquisition, and with Cannibble issuing up to another 20% (of the number of Cannibble shares issued and outstanding at closing) of Cannibble Shares to the vendors subject to Eshbal achieving certain sales or profitability milestones within six years of closing.
The completion of the proposed acquisition is subject to the negotiation and signing of a definitive agreement in respect of the proposed acquisition, completion of due diligence by the parties, completion of a private placement by Cannibble of minimum financing of C$4,000,000, receipt of all applicable governmental, regulatory and contractual third party approvals, including approval of the Canadian Securities Exchange, and other conditions precedent and closing conditions customary for similar transactions to the Proposed Acquisition.
“The proposed acquisition of Eshbal will mark a significant step in Cannibble’s development and coincides with the growth in consumer demand for gluten/sugar-free products, vegan, dietary supplements, and milk and meat substitutes. Our intention with this proposed acquisition is to position Cannibble as a leader in the US health and wellness “better-for-you” market, which is predicted to reach US$298.3 billion in 2022.”
Yoav Bar-Joseph, CEO and director of Cannibble
“The merger of Eshbal and Cannibble directly fits the strategy of both companies. Eshbal brings unique know-how and food technology, while Cannibble brings North American market experience and presence. We believe that the accumulated experience of both managements will drive market success and quick growth of the combined company in this high-growth sector of “better-for-you” food products.”
Yuval Levy, Chairman of Eshbal Functional Foods
Cannibble Foodtech (PLCN.CN) announced a huge milestone. This recent news shows Cannibble is building its structure to become a major player in the US health and wellness “better-for-you” market. At a time when companies suffer from general market turmoil, the company reveals to be a strong company with a considerable upside.
* HACCP is a management system in which food safety is addressed through the analysis and control of biological, chemical, and physical hazards from raw material production, procurement, and handling, to manufacturing, distribution, and consumption of the finished product.
** GMPs are the primary operational and environmental conditions required to produce safe foods. They ensure that ingredients, products, and packaging materials are handled safely and those food products are processed in a suitable environment.
Marc has been involved in the Stock Market Media Industry for the last +4 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Media where he was head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including technology, metals & mining markets.
©2024 10xAlerts